Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome.
about
The sequence of human chromosome 21 and implications for research into Down syndromeProspects for Improving Brain Function in Individuals with Down SyndromeEmerging pharmacotherapies for neurodevelopmental disordersMouse models of Down syndrome as a tool to unravel the causes of mental disabilitiesEffects of neonatal neural progenitor cell implantation on adult neuroanatomy and cognition in the Ts65Dn model of Down syndromePrincipal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down SyndromeSynaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down SyndromeAmyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegenerationAnimal models of intellectual disability: towards a translational approachXLMR candidate mouse gene, Zcchc12 (Sizn1) is a novel marker of Cajal-Retzius cellsComprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.Live imaging of neuronal connections by magnetic resonance: Robust transport in the hippocampal-septal memory circuit in a mouse model of Down syndrome.Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.Molecular basis of pharmacotherapies for cognition in Down syndromeGene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome.Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndromeThe TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion.Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice.Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia.Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndromeMaternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic miceDown syndrome and Alzheimer's disease: a link between development and aging.Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice.Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.Down syndrome--recent progress and future prospects.Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).Designer receptors enhance memory in a mouse model of Down syndrome.Understanding mental retardation in Down's syndrome using trisomy 16 mouse models.Sleep-like behavior and 24-h rhythm disruption in the Tc1 mouse model of Down syndromeGalantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome.Age-related neurodegeneration and memory loss in down syndrome.Working memory in the aged Ts65Dn mouse, a model for Down syndromeAdult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.CNS gene therapy and a nexus of complexity: systems and biology at a crossroads.Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease.Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
P2860
Q21194900-7D50EDA4-30E7-45B6-94E5-8FB1FCD67943Q22252566-D845C64E-42EE-4631-A4AD-37F0AE4FF248Q24619170-FE00E3AA-DEA6-46D8-97B6-8329299502A5Q26863005-CDDF5D74-7DDB-4BD5-871D-02F1C6E1A514Q27303804-B78CB1E3-CBAC-4156-B386-DC0F78F83381Q27322212-D31B9402-BDED-47BD-B1F3-350765D59F4AQ27324486-4F75C266-27B3-4B2D-A870-268E0E0C6173Q27331605-63311D03-A66D-43F5-8392-E3337967CFBBQ28389500-D64BA311-E64F-4FB0-AE2D-79DBA95FE8B6Q28591839-51CE5886-39E0-4936-A597-3E71E3B8E534Q30459302-AE06A4D2-6AA5-48F7-8670-EC99743F4B93Q30480616-53EC9C39-B436-479D-8BA2-28031857F6A2Q33598454-377D53B5-82EE-4D60-9E21-5725CAEE41CEQ33625613-5C78DFB5-2BF4-4B06-8AF1-C6ABC2B29E5AQ33641252-0A3B7885-2460-429A-9F69-AF2654D5C2E2Q33643589-14D693DF-F29E-4F96-880A-9CF65AA54FFBQ33896035-6741361D-B135-49D1-B7A0-BED9716ED645Q33943282-D99DA995-E65E-49D1-BC5F-2D9B6EAAE2B4Q34046354-25B9517A-EC04-4967-A374-4E0CBE32DF1DQ34084791-09AE7C12-AE36-4ED2-9552-A8880FA2D11DQ34125605-A38DDC47-9BC5-432F-AC82-8FD5F07C1B0CQ34204889-09734CDD-B3BF-41EA-B414-A1399B20F3FDQ34365576-334CB6B3-5D54-4CFA-8D63-014D17620507Q34366691-47370216-A9B7-468B-8685-5ED55114F682Q34454393-2832DF48-9E74-45E3-B2AE-63493A7BDC92Q34514070-6C83B993-B33C-4151-8EFF-8F298C2A0F44Q34918986-E93D58FE-C7E4-4D5B-962B-F7030D7145C7Q34964947-0B1202C7-AAE9-424C-B86F-578442B19E5FQ34979826-41E7993C-FD79-41AE-9290-358C8B32C454Q35020182-D6610BFF-35D3-484E-AD7A-6CC5546786F4Q35204307-D9A38E7C-BB43-4DBB-A586-13543798CC7DQ35538343-CC7254FC-223F-46FA-A0BA-0242B2466FD0Q35551607-109A5A4A-04B9-4ABC-AE69-509B55A967E8Q35867093-74EA0AEC-C2FD-4D7B-9018-260B01A33409Q36004329-337C6EDD-C849-45C2-BECD-9FAA00A63A94Q36119092-3EEC61A1-FBF2-413D-97F5-2A6D9DE91CC7Q36465744-2404BF77-F765-49D1-96D0-EFC3D8DF5136Q36485942-A0C1F079-EB4E-4DFE-961A-8AF5E9536153Q36522425-BBECEB48-467C-4EDE-A78E-8E5A680F6609Q36522433-0380DF71-E3D0-438E-A490-7AAF42FB24D3
P2860
Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@en
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@nl
type
label
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@en
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@nl
prefLabel
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@en
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@nl
P2093
P356
P1476
Loss of cholinergic phenotype ...... ouse model of Down's syndrome.
@en
P2093
A C Granholm
L A Sanders
P304
P356
10.1006/EXNR.1999.7289
P407
P577
2000-02-01T00:00:00Z